How much funding has Affimed raised?

Affimed has raised $101.0M in total funding, most recently a Series E round.

Who are Affimed's investors?

Affimed's investors include OrbiMed, Aeris Capital, Public Investment Fund, LSP Life Sciences Partners, Novo Nordisk, BioMedPartners.

Where is Affimed headquartered?

Affimed is headquartered in Heidelberg, Germany.

What industry is Affimed in?

Affimed operates in Biotech, Oncology.

Affimed

IPO

Public · Heidelberg, Germany · Founded 2000 · $101.0M raised

Biotech

Oncology

Headquarters: Heidelberg
Employees: 51–200
Founded: 2000
Business Model: B2B
Website: affimed.com

Total Funding: $101.0M
Last Round: $19.4M Series ESep 2014
Rounds: 5
Type: Public

About

Affimed is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing innate cell engager (ICE) therapies for oncology. Its proprietary tetravalent bispecific antibody platform redirects NK cells and macrophages to tumor cells by binding CD16A on innate immune effector cells and tumor-associated antigens such as EGFR (AFM24) and CD123 (AFM28). Affimed trades on NASDAQ under the ticker AFMD.

Summary

Affimed is a Biotech company based in Heidelberg, Germany, founded in 2000. It has raised $101.0M in total across 5 rounds, most recently a $19.4M Series E round in Sep 2014. Investors include OrbiMed, Aeris Capital and Public Investment Fund.